Abstract
Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid mediator that regulates several processes important for hematologic cancer progression. S1P is generated by two sphingosine kinases, SphK1 and SphK2, and is exported outside the cell, where it activates specific cell surface S1P G-protein coupled receptors in autocrine/paracrine manner, coined “inside-out signaling”. In this review, we highlight the importance of SphK1 and inside-out signaling by S1P in hematologic malignancy. We also summarize the results of studies targeting the SphK1/S1P/S1P receptor axis and the effects of the S1P receptor modulator, FTY720, in hematologic malignancy.
Keywords: Sphingosine-1-phosphate, sphingosine kinase, sphingosine-1-phosphate receptors, leukemia, lymphoma, hematologic malignancies, cytokines stimulate, GPCR, UDP-glucose, DLBCL, siRNA, DMS
Anti-Cancer Agents in Medicinal Chemistry
Title: Targeting Sphingosine-1-Phosphate in Hematologic Malignancies
Volume: 11 Issue: 9
Author(s): Christina E. Stevenson, Kazuaki Takabe, Masayuki Nagahashi, Sheldon Milstien and Sarah Spiegel
Affiliation:
Keywords: Sphingosine-1-phosphate, sphingosine kinase, sphingosine-1-phosphate receptors, leukemia, lymphoma, hematologic malignancies, cytokines stimulate, GPCR, UDP-glucose, DLBCL, siRNA, DMS
Abstract: Sphingosine-1-phosphate (S1P) is a pleiotropic bioactive lipid mediator that regulates several processes important for hematologic cancer progression. S1P is generated by two sphingosine kinases, SphK1 and SphK2, and is exported outside the cell, where it activates specific cell surface S1P G-protein coupled receptors in autocrine/paracrine manner, coined “inside-out signaling”. In this review, we highlight the importance of SphK1 and inside-out signaling by S1P in hematologic malignancy. We also summarize the results of studies targeting the SphK1/S1P/S1P receptor axis and the effects of the S1P receptor modulator, FTY720, in hematologic malignancy.
Export Options
About this article
Cite this article as:
E. Stevenson Christina, Takabe Kazuaki, Nagahashi Masayuki, Milstien Sheldon and Spiegel Sarah, Targeting Sphingosine-1-Phosphate in Hematologic Malignancies, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (9) . https://dx.doi.org/10.2174/187152011797655122
DOI https://dx.doi.org/10.2174/187152011797655122 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
AIDS Related Viruses, their Association with Leukemia, and Raf Signaling
Current HIV Research Antagonists of Growth Hormone-Releasing Hormone in Oncology
Combinatorial Chemistry & High Throughput Screening DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Protein Degradation by the Ubiquitin-Proteasome Pathway and Organ Fibrosis
Current Medicinal Chemistry Molecular Mechanisms of Epigenetic Regulators as Activatable Targets in Cancer Theranostics
Current Medicinal Chemistry Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)
Current Pharmacogenomics Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Discovery of Multi-target Anticancer Agents Based on HDAC Inhibitor MS-275 and 5-FU
Medicinal Chemistry Structure-Function Relationships and Clinical Applications of L-Asparaginases
Current Medicinal Chemistry The Quest for a Tumor Suppressor Gene Phenotype
Current Molecular Medicine Detection of Clonal Immunoglobulin and T-Cell Receptor Gene Recombination in Hematological Malignancies: Monitoring Minimal Residual Disease
Cardiovascular & Hematological Disorders-Drug Targets Potential Novel Targets in Breast Cancer
Current Pharmaceutical Biotechnology Characterization of MHC Ligands for Peptide Based Tumor Vaccination
Current Pharmaceutical Design Ganoderma lucidum: A Potent Pharmacological Macrofungus
Current Pharmaceutical Biotechnology Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity
Mini-Reviews in Medicinal Chemistry PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
Current Medicinal Chemistry Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design